Article received: meijs, t.E.(2020).Epinephrine stress testing during cardiac catheterization in patients with aortic coarctation.American heart journal, 78-87.Purpose: we aimed to investigate whether epinephrine stress testing improves clinical decision making and outcome in coa.Method: we retrospectively evaluated coa patients (b)(6) kg with a peak systolic gradient (psg) =20 mm hg during cardiac catheterization who underwent epinephrine stress testing.Subsequent interventional management (stenting or balloon dilatation), complications, and medium-term clinical outcome were assessed.Conclusion: in coa patients with a low baseline psg but high epinephrine psg, percutaneous intervention is associated with a substantial reduction in systemic blood pressure and the use of antihypertensive medication.Per the article product problems included stent fracture and stent migration.
|
Article reviewed: meijs, et al.(2020).Epinephrine stress testing during cardiac catheterization in patients with aortic coarctation.Am heart journal; 225:78-87.The subject article is retrospective observational study of 50 patients with aortic coarctation (coa) who were >50 kg with a peak systolic gradient (psg) =20 mm hg during cardiac catheterization who underwent epinephrine stress testing.Subsequent interventional management (stenting or balloon dilatation), complications, and medium-term clinical outcome were assessed.This complaint is based on information found within a article/literature review.There was no product that was available for evaluation, therefore a device evaluation could not be conducted and the complaint cannot be confirmed.The author of the article did not report any major adverse patient effects as result of this event.A device history record (dhr) review was unable to be performed as the device product part number and lot number was not provided within the article.Attempts to obtain the device lot information was conducted but unsuccessful.The hazardous situation/harm is addressed in the risk file and is operating within its risk profile.There was no evidence within the article that the device was the cause of the reported event.The complaint history review did not identify an adverse trend, therefore no escalation to capa process is required.Conclusion: considering the retrospective observational design of the study with a relatively small sample size, high technical success rate, and the fact that percutaneous intervention is associated with a substantial reduction in systemic blood pressure and the use of antihypertensive medication, one can infer that getinge¿s advanta v12tm balloon expandable covered stents performed as expected.The authors do not attribute development of complications to any particular stent type.H3 other text: not available for return.
|